Genetic variants and animal models in SNCA and Parkinson disease

Ageing Research Reviews

Volumn 15, Issue 1, 2014, Pages 161-176

  Deng, Hao ^a   Yuan, Lamei ^a  

^a THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Genetics; Multiplication; Mutation; Parkinson disease; SNCA gene; Variation

Indexed keywords

ALPHA SYNUCLEIN;

ANIMAL MODEL; CAENORHABDITIS ELEGANS; DOPAMINERGIC NERVE CELL; FRUIT FLY MODEL; GENE DUPLICATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; LEWY BODY; MISSENSE MUTATION; MONKEY MODEL; MOUSE MODEL; NONHUMAN; PARKINSON DISEASE; POINT MUTATION; RAT MODEL; REVIEW; TRANSGENIC MOUSE; ANIMAL; DISEASE MODEL; DROSOPHILA; GENETICS; HAPLORHINI; HUMAN; MOUSE; RAT;

ALPHA-SYNUCLEIN; ANIMALS; CAENORHABDITIS ELEGANS; DISEASE MODELS, ANIMAL; DROSOPHILA; GENETIC VARIATION; HAPLORHINI; HUMANS; MICE; PARKINSON DISEASE; RATS;

EID: 84899811573     PISSN: 15681637     EISSN: 18729649     Source Type: Journal    
DOI: 10.1016/j.arr.2014.04.002     Document Type: Review

References (238)

1. Abeliovich A., Schmitz Y., Fariñas I., Choi-Lundberg D., Ho W.H., Castillo P.E., Shinsky N., Verdugo J.M., Armanini M., Ryan A., Hynes M., Phillips H., Sulzer D., Rosenthal A. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000, 25:239-252.
2. Ahn T.B., Kim S.Y., Kim J.Y., Park S.S., Lee D.S., Min H.J., Kim Y.K., Kim S.E., Kim J.M., Kim H.J., Cho J., Jeon B.S. alpha-Synuclein gene duplication is present in sporadic Parkinson disease. Neurology 2008, 70:43-49.
3. Alcalay R.N., Caccappolo E., Mejia-Santana H., Tang M.X., Rosado L., Ross B.M., Verbitsky M., Kisselev S., Louis E.D., Comella C., Colcher A., Jennings D., Nance M.A., Bressman S.B., Scott W.K., Tanner C., Mickel S., Andrews H., Waters C., Fahn S., Cote L., Frucht S., Ford B., Rezak M., Novak K., Friedman J.H., Pfeiffer R., Marsh L., Hiner B., Siderowf A., Ottman R., Marder K., Clark L.N. Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. Arch. Neurol. 2010, 67:1116-1122.
4. Alieva A.K., Shadrina M.I., Filatova E.V., Ustinova V.V., Fedotova E.Y., Karabanov A.V., Illarioshkin S.N., Slominsky P.A. Polymorphisms in the SNCA gene: association with the risk of development of the sporadic form of Parkinson's disease and the level of SNCA gene expression in peripheral blood of patients from Russia. Neurosci. Med. 2013, 4:208-214.
5. Alvarez-Fischer D., Henze C., Strenzke C., Westrich J., Ferger B., Höglinger G.U., Oertel W.H., Hartmann A. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice. Exp. Neurol. 2008, 210:182-193.
6. Appel-Cresswell S., Vilarino-Guell C., Encarnacion M., Sherman H., Yu I., Shah B., Weir D., Thompson C., Szu-Tu C., Trinh J., Aasly J.O., Rajput A., Rajput A.H., Jon Stoessl A., Farrer M.J. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov. Disord. 2013, 28:811-813.
7. Athanassiadou A., Voutsinas G., Psiouri L., Leroy E., Polymeropoulos M.H., Ilias A., Maniatis G.M., Papapetropoulos T. Genetic analysis of families with Parkinson disease that carry the Ala53Thr mutation in the gene encoding alpha-synuclein. Am. J. Hum. Genet. 1999, 65:555-558.
8. Autere J.M., Hiltunen M.J., Mannermaa A.J., Jäkälä P.A., Hartikainen P.H., Majamaa K., Alafuzoff I., Soininen H.S. Molecular genetic analysis of the alpha-synuclein and the parkin gene in Parkinson's disease in Finland. Eur. J. Neurol. 2002, 9:479-483.
9. Azeredo da Silveira S., Schneider B.L., Cifuentes-Diaz C., Sage D., Abbas-Terki T., Iwatsubo T., Unser M., Aebischer P. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. Hum. Mol. Genet. 2009, 18:872-887.
10. Bartels T., Choi J.G., Selkoe D.J. alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 2011, 477:107-110.
11. Bayersdorfer F., Voigt A., Schneuwly S., Botella J.A. Dopamine-dependent neurodegeneration in Drosophila models of familial and sporadic Parkinson's disease. Neurobiol. Dis. 2010, 40:113-119.
12. Bennett P., Nicholl D.J. Absence of the G209A mutation in the alpha-synuclein gene in British families with Parkinson's disease. Neurology 1998, 50:1183.
13. Berg D., Niwar M., Maass S., Zimprich A., Möller J.C., Wuellner U., Schmitz-Hübsch T., Klein C., Tan E.K., Schöls L., Marsh L., Dawson T.M., Janetzky B., Müller T., Woitalla D., Kostic V., Pramstaller P.P., Oertel W.H., Bauer P., Krueger R., Gasser T., Riess O. Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1,900 patients. Mov. Disord. 2005, 20:1191-1194.
14. Beyer K., Domingo-Sábat M., Lao J.I., Carrato C., Ferrer I., Ariza A. Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases. Neurogenetics 2008, 9:15-23.
15. Beyer K. Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol. 2006, 112:237-251.
16. Bras J., Guerreiro R., Ribeiro M., Morgadinho A., Januario C., Dias M., Calado A., Semedo C., Oliveira C., Hardy J., Singleton A. Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2. BMC Neurol. 2008, 8:1.
17. Brueggemann N., Odin P., Gruenewald A., Tadic V., Hagenah J., Seidel G., Lohmann K., Klein C., Djarmati A. Re: Alpha-synuclein gene duplication is present in sporadic Parkinson disease. Neurology 2008, 71:1294.
18. Bonifati V., Vaughan J.R., Fabrizio E., Volpe G., De Michele G., Filla A., Meco G., Wood N. A screening for Ala53Thr mutation in alpha-synuclein gene in Italian families with Parkinson's disease. J. Neurol. 1999, 246:I/169. The Italian Parkinson Genetics Study Group, the European Consortium on Genetic Susceptibility in Parkinson's disease.
19. Bostantjopoulou S., Katsarou Z., Papadimitriou A., Veletza V., Hatzigeorgiou G., Lees A. Clinical features of parkinsonian patients with the alpha-synuclein (G209A) mutation. Mov. Disord. 2001, 16:1007-1013.
20. Burré J., Sharma M., Tsetsenis T., Buchman V., Etherton M.R., Südhof T.C. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 2010, 329:1663-1667.
21. Cabin D.E., Gispert-Sanchez S., Murphy D., Auburger G., Myers R.R., Nussbaum R.L. Exacerbated synucleinopathy in mice expressing A53T SNCA on a Snca null background. Neurobiol. Aging 2005, 26:25-35.
22. Cabin D.E., Shimazu K., Murphy D., Cole N.B., Gottschalk W., Mcilwain K.L., Orrison B., Chen A., Ellis C.E., Paylor R., Lu B., Nussbaum R.L. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci. 2002, 22:8797-8807.
23. Camargos S.T., Dornas L.O., Momeni P., Lees A., Hardy J., Singleton A., Cardoso F. Familial Parkinsonism and early onset Parkinson's disease in a Brazilian movement disorders clinic: phenotypic characterization and frequency of SNCA, PRKN, PINK1, and LRRK2 mutations. Mov. Disord. 2009, 24:662-666.
24. Cannon J.R., Geghman K.D., Tapias V., Sew T., Dail M.K., Li C., Greenamyre J.T. Expression of human E46K-mutated alpha-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment. Exp. Neurol. 2013, 240:44-56.
25. Cardo L.F., Coto E., de Mena L., Ribacoba R., Lorenzo-Betancor O., Pastor P., Samaranch L., Mata I.F., Díaz M., Moris G., Menéndez M., Corao A.I., Alvarez V. A search for SNCA 3' UTR variants identified SNP rs356165 as a determinant of disease risk and onset age in Parkinson's disease. J. Mol. Neurosci. 2012, 47:425-430.
26. Carr J., de la Fuente-Fernández R., Schulzer M., Mak E., Calne S.M., Calne D.B. Familial and sporadic Parkinson's disease usually display the same clinical features. Parkinsonism Relat. Disord. 2003, 9:201-204.
27. Chan D.K., Mellick G., Cai H., Wang X.L., Ng P.W., Pang C.P., Woo J., Kay R. The alpha-synuclein gene and Parkinson disease in a Chinese population. Arch. Neurol. 2000, 57:501-503.
28. Chan P., Tanner C.M., Jiang X., Langston J.W. Failure to find the alpha-synuclein gene missense mutation (G209A) in 100 patients with younger onset Parkinson's disease. Neurology 1998, 50:513-514.
29. Chan P., Jiang X., Forno L.S., Di Monte D.A., Tanner C.M., Langston J.W. Absence of mutations in the coding region of the alpha-synuclein gene in pathologically proven Parkinson's disease. Neurology 1998, 50:1136-1137.
30. Chartier-Harlin M.C., Kachergus J., Roumier C., Mouroux V., Douay X., Lincoln S., Levecque C., Larvor L., Andrieux J., Hulihan M., Waucquier N., Defebvre L., Amouyel P., Farrer M., Destée A. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004, 364:1167-1169.
31. Chen L., Feany M.B. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat. Neurosci. 2005, 8:657-663.
32. Chen P.E., Specht C.G., Morris R.G., Schoepfer R. Spatial learning is unimpaired in mice containing a deletion of the alpha-synuclein locus. Eur. J. Neurosci. 2002, 16:154-158.
33. Chesselet M.F. In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease?. Exp. Neurol. 2008, 209:22-27.
34. Choi J.M., Woo M.S., Ma H.I., Kang S.Y., Sung Y.H., Yong S.W., Chung S.J., Kim J.S., Shin H.W., Lyoo C.H., Lee P.H., Baik J.S., Kim S.J., Park M.Y., Sohn Y.H., Kim J.H., Kim J.W., Lee M.S., Lee M.C., Kim D.H., Kim Y.J. Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease. Neurogenetics 2008, 9:263-269.
35. Cronin K.D., Ge D., Manninger P., Linnertz C., Rossoshek A., Orrison B.M., Bernard D.J., El-Agnaf O.M., Schlossmacher M.G., Nussbaum R.L., Chiba-Falek O. Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain. Hum. Mol. Genet. 2009, 18:3274-3285.
36. Crosiers D., Theuns J., Cras P., Van Broeckhoven C. Parkinson disease: insights in clinical, genetic and pathological features of monogenic disease subtypes. J. Chem. Neuroanat. 2011, 42:131-141.
37. Darvish H., Movafagh A., Omrani M.D., Firouzabadi S.G., Azargashb E., Jamshidi J., Khaligh A., Haghnejad L., Naeini N.S., Talebi A., Heidari-Rostami H.R., Noorollahi-Moghaddam H., Karkheiran S., Shahidi G.A., Paknejad S.M., Ashrafian H., Abdi S., Kayyal M., Akbari M., Pedram N., Emamalizadeh B. Detection of copy number changes in genes associated with Parkinson's disease in Iranian patients. Neurosci. Lett. 2013, 551:75-78.
38. Dauer W., Kholodilov N., Vila M., Trillat A.C., Goodchild R., Larsen K.E., Staal R., Tieu K., Schmitz Y., Yuan C.A., Rocha M., Jackson-Lewis V., Hersch S., Sulzer D., Przedborski S., Burke R., Hen R. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:14524-14529.
39. Deng H., Liang H., Jankovic J. F-box only protein 7 gene in parkinsonian-pyramidal disease. JAMA Neurol. 2013, 70:20-24.
40. Deng H., Gao K., Jankovic J. The genetics of Tourette syndrome. Nat. Rev. Neurol. 2012, 8:203-213.
41. Deng H., Xie W., Guo Y., Le W., Jankovic J. Gene dosage analysis of alpha-synuclein (SNCA) in patients with Parkinson's disease. Mov. Disord. 2006, 21:728-729.
42. El-Agnaf O.M., Curran M.D., Wallace A., Middleton D., Murgatroyd C., Curtis A., Perry R., Jaros E. Mutation screening in exons 3 and 4 of alpha-synuclein in sporadic Parkinson's and sporadic and familial dementia with Lewy bodies cases. Neuroreport 1998, 9:3925-3927.
43. Elbaz A., Ross O.A., Ioannidis J.P., Soto-Ortolaza A.I., Moisan F., Aasly J., Annesi G., Bozi M., Brighina L., Chartier-Harlin M.C., Destée A., Ferrarese C., Ferraris A., Gibson J.M., Gispert S., Hadjigeorgiou G.M., Jasinska-Myga B., Klein C., Krüger R., Lambert J.C., Lohmann K., van de Loo S., Loriot M.A., Lynch T., Mellick G.D., Mutez E., Nilsson C., Opala G., Puschmann A., Quattrone A., Sharma M., Silburn P.A., Stefanis L., Uitti R.J., Valente E.M., Vilariño-Güell C., Wirdefeldt K., Wszolek Z.K., Xiromerisiou G., Maraganore D.M., Farrer M.J. Independent and joint effects of the MAPT and SNCA genes in Parkinson disease. Ann. Neurol. 2011, 69:778-792. Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium.
44. Elia A.E., Petrucci S., Fasano A., Guidi M., Valbonesi S., Bernardini L., Consoli F., Ferraris A., Albanese A., Valente E.M. Alpha-synuclein gene duplication: marked intrafamilial variability in two novel pedigrees. Mov. Disord. 2013, 28:813-817.
45. Emmer K.L., Waxman E.A., Covy J.P., Giasson B.I. E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment. J. Biol. Chem. 2011, 286:35104-35118.
46. Farrer M., Kachergus J., Forno L., Lincoln S., Wang D.S., Hulihan M., Maraganore D., Gwinn-Hardy K., Wszolek Z., Dickson D., Langston J.W. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann. Neurol. 2004, 55:174-179.
47. Farrer M., Maraganore D.M., Lockhart P., Singleton A., Lesnick T.G., de Andrade M., West A., de Silva R., Hardy J., Hernandez D. alpha-Synuclein gene haplotypes are associated with Parkinson's disease. Hum. Mol. Genet 2001, 10:1847-1851.
48. Farrer M., Wavrant-De Vrieze F., Crook R., Boles L., Perez-Tur J., Hardy J., Johnson W.G., Steele J., Maraganore D., Gwinn K., Lynch T. Low frequency of alpha-synuclein mutations in familial Parkinson's disease. Ann. Neurol. 1998, 43:394-397.
49. Feany M.B., Bender W.W. A Drosophila model of Parkinson's disease. Nature 2000, 404:394-398.
50. Fleming S.M., Mulligan C.K., Richter F., Mortazavi F., Lemesre V., Frias C., Zhu C., Stewart A., Gozes I., Morimoto B., Chesselet M.F. A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions. Mol. Cell. Neurosci. 2011, 46:597-606.
51. Fleming S.M., Tetreault N.A., Mulligan C.K., Hutson C.B., Masliah E., Chesselet M.F. Olfactory deficits in mice overexpressing human wildtype alpha-synuclein. Eur. J. Neurosci. 2008, 28:247-256.
52. Fleming S.M., Salcedo J., Fernagut P.O., Rockenstein E., Masliah E., Levine M.S., Chesselet M.F. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J. Neurosci. 2004, 24:9434-9440.
53. Fuchs J., Tichopad A., Golub Y., Munz M., Schweitzer K.J., Wolf B., Berg D., Mueller J.C., Gasser T. Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J. 2008, 22:1327-1334.
54. Fuchs J., Nilsson C., Kachergus J., Munz M., Larsson E.M., Schüle B., Langston J.W., Middleton F.A., Ross O.A., Hulihan M., Gasser T., Farrer M.J. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 2007, 68:916-922.
55. Gao H.M., Zhang F., Zhou H., Kam W., Wilson B., Hong J.S. Neuroinflammation and alpha-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease. Environ. Health Perspect. 2011, 119:807-814.
56. Garraux G., Caberg J.H., Vanbellinghen J.F., Jamar M., Bours V., Moonen G., Dive D. Partial trisomy 4q associated with young-onset dopa-responsive parkinsonism. Arch. Neurol. 2012, 69:398-400.
57. George S., van den Buuse M., San Mok S., Masters C.L., Li Q.X., Culvenor J.G. Alpha-synuclein transgenic mice exhibit reduced anxiety-like behaviour. Exp. Neurol. 2008, 210:788-792.
58. Giasson B.I., Duda J.E., Quinn S.M., Zhang B., Trojanowski J.Q., Lee V.M. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 2002, 34:521-533.
59. Gispert S., Trenkwalder C., Mota-Vieira L., Kostic V., Auburger G. Failure to find alpha-synuclein gene dosage changes in 190 patients with familial Parkinson disease. Arch. Neurol. 2005, 62:96-98.
60. Gispert S., Del Turco D., Garrett L., Chen A., Bernard D.J., Hamm-Clement J., Korf H.W., Deller T., Braak H., Auburger G., Nussbaum R.L. Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol. Cell. Neurosci. 2003, 24:419-429.
61. Gomez-Isla T., Irizarry M.C., Mariash A., Cheung B., Soto O., Schrump S., Sondel J., Kotilinek L., Day J., Schwarzschild M.A., Cha J.H., Newell K., Miller D.W., Uéda K., Young A.B., Hyman B.T., Ashe K.H. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice. Neurobiol. Aging 2003, 24:245-258.
62. Gorbatyuk O.S., Li S., Sullivan L.F., Chen W., Kondrikova G., Manfredsson F.P., Mandel R.J., Muzyczka N. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:763-768.
63. Goris A., Williams-Gray C.H., Clark G.R., Foltynie T., Lewis S.J., Brown J., Ban M., Spillantini M.G., Compston A., Burn D.J., Chinnery P.F., Barker R.A., Sawcer S.J. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann. Neurol. 2007, 62:145-153.
64. Graham D.R., Sidhu A. Mice expressing the A53T mutant form of human alpha-synuclein exhibit hyperactivity and reduced anxiety-like behavior. J. Neurosci. Res. 2010, 88:1777-1783.
65. Hadjigeorgiou G.M., Xiromerisiou G., Gourbali V., Aggelakis K., Scarmeas N., Papadimitriou A., Singleton A. Association of alpha-synuclein Rep1 polymorphism and Parkinson's disease: influence of Rep1 on age at onset. Mov. Disord. 2006, 21:534-539.
66. Hallett P.J., Mclean J.R., Kartunen A., Langston J.W., Isacson O. alpha-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits. Neurobiol. Dis. 2012, 47:258-267.
67. Higuchi S., Arai H., Matsushita S., Matsui T., Kimpara T., Takeda A., Shirakura K. Mutation in the alpha-synuclein gene and sporadic Parkinson's disease, Alzheimer's disease, and dementia with lewy bodies. Exp. Neurol. 1998, 153:164-166.
68. Ho S.L., Kung M.H. G209A mutation in the alpha-synuclein gene is rare and not associated with sporadic Parkinson's disease. Mov. Disord. 1998, 13:970-971.
69. Hofer A., Berg D., Asmus F., Niwar M., Ransmayr G., Riemenschneider M., Bonelli S.B., Steffelbauer M., Ceballos-Baumann A., Haussermann P., Behnke S., Krüger R., Prestel J., Sharma M., Zimprich A., Riess O., Gasser T. The role of alpha-synuclein gene multiplications in early-onset Parkinson's disease and dementia with Lewy bodies. J. Neural Transm. 2005, 112:1249-1254.
70. Hoffman-Zacharska D., Koziorowski D., Ross O.A., Milewski M., Poznański J., Jurek M., Wszolek Z.K., Soto-Ortolaza A., Slawek J., Janik P., Jamrozik Z., Potulska-Chromik A., Jasińska-Myga B., Opala G., Krygowska-Wajs A., Czyzewski K., Dickson D.W., Bal J., Friedman A. Novel A18T and pA29S substitutions in alpha-synuclein may be associated with sporadic Parkinson's disease. Parkinsonism Relat. Disord. 2013, 19:1057-1060.
71. Hope A.D., Myhre R., Kachergus J., Lincoln S., Bisceglio G., Hulihan M., Farrer M.J. Alpha-synuclein missense and multiplication mutations in autosomal dominant Parkinson's disease. Neurosci. Lett. 2004, 367:97-100.
72. Hu C.J., Sung S.M., Liu H., Chang J.G. No mutation of G209A in the alpha-synuclein gene in sporadic Parkinson's disease among Taiwan Chinese. Eur. Neurol. 1999, 41:85-87.
73. Hu Y., Tang B., Guo J., Wu X., Sun Q., Shi C., Hu L., Wang C., Wang L., Tan L., Shen L., Yan X., Zhang H. Variant in the 3' region of SNCA associated with Parkinson's disease and serum alpha-synuclein levels. J. Neurol. 2012, 259:497-504.
74. Ibáñez P., Lesage S., Janin S., Lohmann E., Durif F., Destée A., Bonnet A.M., Brefel-Courbon C., Heath S., Zelenika D., Agid Y., Dürr A., Brice A. Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. Arch. Neurol. 2009, 66:102-108. French Parkinson's Disease Genetics Study Group.
75. Ibáñez P., Bonnet A.M., Débarges B., Lohmann E., Tison F., Pollak P., Agid Y., Dürr A., Brice A. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 2004, 364:1169-1171.
76. Ikeuchi T., Kakita A., Shiga A., Kasuga K., Kaneko H., Tan C.F., Idezuka J., Wakabayashi K., Onodera O., Iwatsubo T., Nishizawa M., Takahashi H., Ishikawa A. Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia. Arch. Neurol. 2008, 65:514-519.
77. Illarioshkin S.N., Ivanova-Smolenskaya I.A., Markova E.D., Zagorovskaya T.B., Brice A. Lack of alpha-synuclein gene mutations in families with autosomal dominant Parkinson's disease in Russia. J. Neurol. 2000, 247:968-969.
78. Itokawa K., Sekine T., Funayama M., Tomiyama H., Fukui M., Yamamoto T., Tamura N., Matsuda H., Hattori N., Araki N. A case of alpha-synuclein gene duplication presenting with head-shaking movements. Mov. Disord. 2013, 28:384-387.
79. Izumi Y., Morino H., Oda M., Maruyama H., Udaka F., Kameyama M., Nakamura S., Kawakami H. Genetic studies in Parkinson's disease with an alpha-synuclein/NACP gene polymorphism in Japan. Neurosci. Lett. 2001, 300:125-127.
80. Janezic S., Threlfell S., Dodson P.D., Dowie M.J., Taylor T.N., Potgieter D., Parkkinen L., Senior S.L., Anwar S., Ryan B., Deltheil T., Kosillo P., Cioroch M., Wagner K., Ansorge O., Bannerman D.M., Bolam J.P., Magill P.J., Cragg S.J., Wade-Martins R. Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E4016-E4025.
81. Johnson J., Hague S.M., Hanson M., Gibson A., Wilson K.E., Evans E.W., Singleton A.A., McInerney-Leo A., Nussbaum R.L., Hernandez D.G., Gallardo M., Mckeith I.G., Burn D.J., Ryu M., Hellstrom O., Ravina B., Eerola J., Perry R.H., Jaros E., Tienari P., Weiser R., Gwinn-Hardy K., Morris C.M., Hardy J., Singleton A.B. SNCA multiplication is not a common cause of Parkinson disease or dementia with Lewy bodies. Neurology 2004, 63:554-556.
82. Kahle P.J., Neumann M., Ozmen L., Müller V., Jacobsen H., Schindzielorz A., Okochi M., Leimer U., van Der Putten H., Probst A., Kremmer E., Kretzschmar H.A., Haass C. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J. Neurosci. 2000, 20:6365-6373.
83. Karamohamed S., Golbe L.I., Mark M.H., Lazzarini A.M., Suchowersky O., Labelle N., Guttman M., Currie L.J., Wooten G.F., Stacy M., Saint-Hilaire M., Feldman R.G., Liu J., Shoemaker C.M., Wilk J.B., Destefano A.L., Latourelle J.C., Xu G., Watts R., Growdon J., Lew M., Waters C., Vieregge P., Pramstaller P.P., Klein C., Racette B.A., Perlmutter J.S., Parsian A., Singer C., Montgomery E., Baker K., Gusella J.F., Herbert A., Myers R.H. Absence of previously reported variants in the SCNA (G88C and G209A), NR4A2 (T291D and T245G) and the DJ-1 (T497C) genes in familial Parkinson's disease from the GenePD study. Mov. Disord. 2005, 20:1188-1191.
84. Karpinar D.P., Balija M.B., Kügler S., Opazo F., Rezaei-Ghaleh N., Wender N., Kim H.Y., Taschenberger G., Falkenburger B.H., Heise H., Kumar A., Riedel D., Fichtner L., Voigt A., Braus G.H., Giller K., Becker S., Herzig A., Baldus M., Jäckle H., Eimer S., Schulz J.B., Griesinger C., Zweckstetter M. Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO J. 2009, 28:3256-3268.
85. Kasten M., Klein C. The many faces of alpha-synuclein mutations. Mov. Disord. 2013, 28:697-701.
86. Kay D.M., Factor S.A., Samii A., Higgins D.S., Griffith A., Roberts J.W., Leis B.C., Nutt J.G., Montimurro J.S., Keefe R.G., Atkins A.J., Yearout D., Zabetian C.P., Payami H. Genetic association between alpha-synuclein and idiopathic Parkinson's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008, 147B:1222-1230.
87. Keyser R.J., Lombard D., Veikondis R., Carr J., Bardien S. Analysis of exon dosage using MLPA in South African Parkinson's disease patients. Neurogenetics 2010, 11:305-312.
88. Khan N., Graham E., Dixon P., Morris C., Mander A., Clayton D., Vaughan J., Quinn N., Lees A., Daniel S., Wood N., de Silva R. Parkinson's disease is not associated with the combined alpha-synuclein/apolipoprotein E susceptibility genotype. Ann. Neurol. 2001, 49:665-668.
89. Khodr C.E., Pedapati J., Han Y., Bohn M.C. Inclusion of a portion of the native SNCA 3'UTR reduces toxicity of human S129A SNCA on striatal-projecting dopamine neurons in rat substantia nigra. Dev. Neurobiol. 2012, 72:906-917.
90. Khodr C.E., Sapru M.K., Pedapati J., Han Y., West N.C., Kells A.P., Bankiewicz K.S., Bohn M.C. An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons. Brain Res. 2011, 1395:94-107.
91. Ki C.S., Stavrou E.F., Davanos N., Lee W.Y., Chung E.J., Kim J.Y., Athanassiadou A. The Ala53Thr mutation in the alpha-synuclein gene in a Korean family with Parkinson disease. Clin. Genet. 2007, 71:471-473.
92. Kiely A.P., Asi Y.T., Kara E., Limousin P., Ling H., Lewis P., Proukakis C., Quinn N., Lees A.J., Hardy J., Revesz T., Houlden H., Holton J.L. alpha-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy?. Acta Neuropathol. 2013, 125:753-769.
93. Kirik D., Annett L.E., Burger C., Muzyczka N., Mandel R.J., Björklund A. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2884-2889.
94. Klein C., Vieregge P., Hagenah J., Sieberer M., Doyle E., Jacobs H., Gasser T., Breakefield X.O., Risch N.J., Ozelius L.J. Search for the PARK3 founder haplotype in a large cohort of patients with Parkinson's disease from northern Germany. Ann. Hum. Genet. 1999, 63:285-291.
95. Kojovic M., Sheerin U.M., Rubio-Agusti I., Saha A., Bras J., Gibbons V., Palmer R., Houlden H., Hardy J., Wood N.W., Bhatia K.P. Young-onset parkinsonism due to homozygous duplication of alpha-synuclein in a consanguineous family. Mov. Disord. 2012, 27:1827-1829.
96. Koprich J.B., Johnston T.H., Huot P., Reyes M.G., Espinosa M., Brotchie J.M. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein. PLoS One 2011, 6:e17698.
97. Koprich J.B., Johnston T.H., Reyes M.G., Sun X., Brotchie J.M. Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease. Mol. Neurodegener. 2010, 5:43.
98. Krüger R., Kuhn W., Leenders K.L., Sprengelmeyer R., Müller T., Woitalla D., Portman A.T., Maguire R.P., Veenma L., Schröder U., Schöls L., Epplen J.T., Riess O., Przuntek H. Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers. Neurology 2001, 56:1355-1362.
99. Krüger R., Vieira-Saecker A.M., Kuhn W., Berg D., Müller T., Kühnl N., Fuchs G.A., Storch A., Hungs M., Woitalla D., Przuntek H., Epplen J.T., Schöls L., Riess O. Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein E genotype. Ann. Neurol. 1999, 45:611-617.
100. Krüger R., Kuhn W., Müller T., Woitalla D., Graeber M., Kösel S., Przuntek H., Epplen J.T., Schöls L., Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 1998, 18:106-108.
101. Kudo T., Loh D.H., Truong D., Wu Y., Colwell C.S. Circadian dysfunction in a mouse model of Parkinson's disease. Exp. Neurol. 2011, 232:66-75.
102. Kuo Y.M., Li Z., Jiao Y., Gaborit N., Pani A.K., Orrison B.M., Bruneau B.G., Giasson B.I., Smeyne R.J., Gershon M.D., Nussbaum R.L. Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum. Mol. Genet. 2010, 19:1633-1650.
103. Kuwahara T., Tonegawa R., Ito G., Mitani S., Iwatsubo T. Phosphorylation of alpha-synuclein protein at Ser-129 reduces neuronal dysfunction by lowering its membrane binding property in Caenorhabditis elegans. J. Biol. Chem. 2012, 287:7098-7109.
104. Kuwahara T., Koyama A., Gengyo-Ando K., Masuda M., Kowa H., Tsunoda M., Mitani S., Iwatsubo T. Familial Parkinson mutant alpha-synuclein causes dopamine neuron dysfunction in transgenic Caenorhabditis elegans. J. Biol. Chem. 2006, 281:334-340.
105. Lakso M., Vartiainen S., Moilanen A.M., Sirviö J., Thomas J.H., Nass R., Blakely R.D., Wong G. Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J. Neurochem. 2003, 86:165-172.
106. Lam H.A., Wu N., Cely I., Kelly R.L., Hean S., Richter F., Magen I., Cepeda C., Ackerson L.C., Walwyn W., Masliah E., Chesselet M.F., Levine M.S., Maidment N.T. Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human alpha-synuclein. J. Neurosci. Res. 2011, 89:1091-1102.
107. Le W., Sayana P., Jankovic J. Animal models of Parkinson's disease: a gateway to therapeutics?. Neurotherapeutics 2014, 11:92-110.
108. Lee M.K., Stirling W., Xu Y., Xu X., Qui D., Mandir A.S., Dawson T.M., Copeland N.G., Jenkins N.A., Price D.L. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53→Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:8968-8973.
109. Lelan F., Boyer C., Thinard R., Rémy S., Usal C., Tesson L., Anegon I., Neveu I., Damier P., Naveilhan P., Lescaudron L. Effects of Human Alpha-Synuclein A53T-A30P Mutations on SVZ and Local Olfactory Bulb Cell Proliferation in a Transgenic Rat Model of Parkinson Disease. Parkinsons Dis. 2011, 2011:987084.
110. Lesage S., Anheim M., Letournel F., Bousset L., Honoré A., Rozas N., Pieri L., Madiona K., Dürr A., Melki R., Verny C., Brice A. G51D alpha-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann. Neurol. 2013, 73:459-471. for the French Parkinson's Disease Genetics (PDG) Study Group.
111. Lesage S., Brice A. Role of mendelian genes in sporadic Parkinson's disease. Parkinsonism Relat. Disord. 2012, 18S1:S66-S70.
112. Lesage S., Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum. Mol. Genet. 2009, 18:R48-R59.
113. Lin J.J., Yueh K.C., Chang D.C., Lin S.Z. Absence of G209A and G88C mutations in the alpha-synuclein gene of Parkinson's disease in a Chinese population. Eur. Neurol. 1999, 42:217-220.
114. Lin X., Parisiadou L., Sgobio C., Liu G., Yu J., Sun L., Shim H., Gu X.L., Luo J., Long C.X., Ding J., Mateo Y., Sullivan P.H., Wu L.G., Goldstein D.S., Lovinger D., Cai H. Conditional expression of Parkinson's disease-related mutant alpha-synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1. J. Neurosci. 2012, 32:9248-9264.
115. Lo Bianco C., Ridet J.L., Schneider B.L., Déglon N., Aebischer P. alpha-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:10813-10818.
116. Lucotte G., Mercier G., Turpin J.C. Lack of mutation G209A in the alpha-synuclein gene in French patients with familial and sporadic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1998, 65:948-949.
117. Macedo M.G., Verbaan D., Fang Y., van Rooden S.M., Visser M., Anar B., Uras A., Groen J.L., Rizzu P., van Hilten J.J., Heutink P. Genotypic and phenotypic characteristics of Dutch patients with early onset Parkinson's disease. Mov. Disord. 2009, 24:196-203.
118. Mamah C.E., Lesnick T.G., Lincoln S.J., Strain K.J., de Andrade M., Bower J.H., Ahlskog J.E., Rocca W.A., Farrer M.J., Maraganore D.M. Interaction of alpha-synuclein and tau genotypes in Parkinson's disease. Ann. Neurol. 2005, 57:439-443.
119. Maraganore D.M., de Andrade M., Elbaz A., Farrer M.J., Ioannidis J.P., Krüger R., Rocca W.A., Schneider N.K., Lesnick T.G., Lincoln S.J., Hulihan M.M., Aasly J.O., Ashizawa T., Chartier-Harlin M.C., Checkoway H., Ferrarese C., Hadjigeorgiou G., Hattori N., Kawakami H., Lambert J.C., Lynch T., Mellick G.D., Papapetropoulos S., Parsian A., Quattrone A., Riess O., Tan E.K., Van Broeckhoven C. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 2006, 296:661-670. Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium.
120. Markopoulou K., Wszolek Z.K., Pfeiffer R.F., Chase B.A. Reduced expression of the G209A alpha-synuclein allele in familial Parkinsonism. Ann. Neurol. 1999, 46:374-381.
121. Marxreiter F., Ettle B., May V.E., Esmer H., Patrick C., Kragh C.L., Klucken J., Winner B., Riess O., Winkler J., Masliah E., Nuber S. Glial A30P alpha-synuclein pathology segregates neurogenesis from anxiety-related behavior in conditional transgenic mice. Neurobiol. Dis. 2013, 59:38-51.
122. Marxreiter F., Nuber S., Kandasamy M., Klucken J., Aigner R., Burgmayer R., Couillard-Despres S., Riess O., Winkler J., Winner B. Changes in adult olfactory bulb neurogenesis in mice expressing the A30P mutant form of alpha-synuclein. Eur. J. Neurosci. 2009, 29:879-890.
123. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., Mucke L. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000, 287:1265-1269.
124. Mata I.F., Yearout D., Alvarez V., Coto E., de Mena L., Ribacoba R., Lorenzo-Betancor O., Samaranch L., Pastor P., Cervantes S., Infante J., Garcia-Gorostiaga I., Sierra M., Combarros O., Snapinn K.W., Edwards K.L., Zabetian C.P. Replication of MAPT and SNCA, but not PARK16-18, as susceptibility genes for Parkinson's disease. Mov. Disord. 2011, 26:819-823.
125. Mata I.F., Shi M., Agarwal P., Chung K.A., Edwards K.L., Factor S.A., Galasko D.R., Ginghina C., Griffith A., Higgins D.S., Kay D.M., Kim H., Leverenz J.B., Quinn J.F., Roberts J.W., Samii A., Snapinn K.W., Tsuang D.W., Yearout D., Zhang J., Payami H., Zabetian C.P. SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch. Neurol. 2010, 67:1350-1356.
126. Matsuoka Y., Vila M., Lincoln S., Mccormack A., Picciano M., Lafrancois J., Yu X., Dickson D., Langston W.J., Mcgowan E., Farrer M., Hardy J., Duff K., Przedborski S., Di Monte D.A. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol. Dis. 2001, 8:535-539.
127. Mccarthy J.J., Linnertz C., Saucier L., Burke J.R., Hulette C.M., Welsh-Bohmer K.A., Chiba-Falek O. The effect of SNCA 3' region on the levels of SNCA-112 splicing variant. Neurogenetics 2011, 12:59-64.
128. Mcfarland N.R., Fan Z., Xu K., Schwarzschild M.A., Feany M.B., Hyman B.T., Mclean P.J. Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. J. Neuropathol. Exp. Neurol. 2009, 68:515-524.
129. Mclean J.R., Hallett P.J., Cooper O., Stanley M., Isacson O. Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression. Mol. Cell. Neurosci. 2012, 49:230-239.
130. Mellick G.D., Siebert G.A., Funayama M., Buchanan D.D., Li Y., Imamichi Y., Yoshino H., Silburn P.A., Hattori N. Screening PARK genes for mutations in early-onset Parkinson's disease patients from Queensland, Australia. Parkinsonism Relat. Disord. 2009, 15:105-109.
131. Mellick G.D., Maraganore D.M., Silburn P.A. Australian data and meta-analysis lend support for alpha-synuclein (NACP-Rep1) as a risk factor for Parkinson's disease. Neurosci. Lett. 2005, 375:112-116.
132. Michell A.W., Barker R.A., Raha S.K., Raha-Chowdhury R. A case of late onset sporadic Parkinson's disease with an A53T mutation in alpha-synuclein. J. Neurol. Neurosurg. Psychiatry 2005, 76:596-597.
133. Mizuta I., Satake W., Nakabayashi Y., Ito C., Suzuki S., Momose Y., Nagai Y., Oka A., Inoko H., Fukae J., Saito Y., Sawabe M., Murayama S., Yamamoto M., Hattori N., Murata M., Toda T. Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease. Hum. Mol. Genet. 2006, 15:1151-1158.
134. Mizuta I., Nishimura M., Mizuta E., Yamasaki S., Ohta M., Kuno S. Meta-analysis of alpha synuclein/NACP polymorphism in Parkinson's disease in Japan. J. Neurol. Neurosurg. Psychiatry 2002, 73:350.
135. Morfis L., Cordato D.J. Dementia with Lewy bodies in an elderly Greek male due to alpha-synuclein gene mutation. J. Clin. Neurosci. 2006, 13:942-944.
136. Moura K.C., Junior M.C., de Rosso A.L., Nicaretta D.H., Pereira J.S., José Silva D., Santos-Reboucas C.B., Pimentel M.M. Exon dosage variations in Brazilian patients with Parkinson's disease: analysis of SNCA, PARKIN, PINK1 and DJ-1 genes. Dis. Markers 2012, 32:173-178.
137. Mueller J.C., Fuchs J., Hofer A., Zimprich A., Lichtner P., Illig T., Berg D., Wüllner U., Meitinger T., Gasser T. Multiple regions of alpha-synuclein are associated with Parkinson's disease. Ann. Neurol. 2005, 57:535-541.
138. Mulcahy P., O'doherty A., Paucard A., O'brien T., Kirik D., Dowd E. The behavioural and neuropathological impact of intranigral AAV-alpha-synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats. Behav. Brain Res. 2013, 243:6-15.
139. Mulcahy P., O'doherty A., Paucard A., O'brien T., Kirik D., Dowd E. Development and characterisation of a novel rat model of Parkinson's disease induced by sequential intranigral administration of AAV-alpha-synuclein and the pesticide, rotenone. Neuroscience 2012, 203:170-179.
140. Muñoz E., Oliva R., Obach V., Martí M.J., Pastor P., Ballesta F., Tolosa E. Identification of Spanish familial Parkinson's disease and screening for the Ala53Thr mutation of the alpha-synuclein gene in early onset patients. Neurosci. Lett. 1997, 235:57-60.
141. Mutez E., Leprêtre F., Le Rhun E., Larvor L., Duflot A., Mouroux V., Kerckaert J.P., Figeac M., Dujardin K., Destée A., Chartier-Harlin M.C. SNCA locus duplication carriers: from genetics to Parkinson disease phenotypes. Hum. Mutat. 2011, 32:E2079-E2090.
142. Myhre R., Toft M., Kachergus J., Hulihan M.M., Aasly J.O., Klungland H., Farrer M.J. Multiple alpha-synuclein gene polymorphisms are associated with Parkinson's disease in a Norwegian population. Acta Neurol. Scand. 2008, 118:320-327.
143. Nagar S., Juyal R.C., Chaudhary S., Behari M., Gupta M., Rao S.N., Thelma B.K. Mutations in the alpha-synuclein gene in Parkinson's disease among Indians. Acta Neurol. Scand. 2001, 103:120-122.
144. Nemani V.M., Lu W., Berge V., Nakamura K., Onoa B., Lee M.K., Chaudhry F.A., Nicoll R.A., Edwards R.H. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 2010, 65:66-79.
145. Nishioka K., Ross O.A., Ishii K., Kachergus J.M., Ishiwata K., Kitagawa M., Kono S., Obi T., Mizoguchi K., Inoue Y., Imai H., Takanashi M., Mizuno Y., Farrer M.J., Hattori N. Expanding the clinical phenotype of SNCA duplication carriers. Mov. Disord. 2009, 24:1811-1819.
146. Nishioka K., Hayashi S., Farrer M.J., Singleton A.B., Yoshino H., Imai H., Kitami T., Sato K., Kuroda R., Tomiyama H., Mizoguchi K., Murata M., Toda T., Imoto I., Inazawa J., Mizuno Y., Hattori N. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann. Neurol. 2006, 59:298-309.
147. Noorian A.R., Rha J., Annerino D.M., Bernhard D., Taylor G.M., Greene J.G. Alpha-synuclein transgenic mice display age-related slowing of gastrointestinal motility associated with transgene expression in the vagal system. Neurobiol. Dis. 2012, 48:9-19.
148. Nuber S., Harmuth F., Kohl Z., Adame A., Trejo M., Schönig K., Zimmermann F., Bauer C., Casadei N., Giel C., Calaminus C., Pichler B.J., Jensen P.H., Müller C.P., Amato D., Kornhuber J., Teismann P., Yamakado H., Takahashi R., Winkler J., Masliah E., Riess O. A progressive dopaminergic phenotype associated with neurotoxic conversion of alpha-synuclein in BAC-transgenic rats. Brain 2013, 136:412-432.
149. Nuber S., Petrasch-Parwez E., Arias-Carrión O., Koch L., Kohl Z., Schneider J., Calaminus C., Dermietzel R., Samarina A., Boy J., Nguyen H.P., Teismann P., Velavan T.P., Kahle P.J., von Hörsten S., Fendt M., Krüger R., Riess O. Olfactory neuron-specific expression of A30P alpha-synuclein exacerbates dopamine deficiency and hyperactivity in a novel conditional model of early Parkinson's disease stages. Neurobiol. Dis. 2011, 44:192-204.
150. Nuytemans K., Theuns J., Cruts M., Van Broeckhoven C. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum. Mutat. 2010, 31:763-780.
151. Nuytemans K., Meeus B., Crosiers D., Brouwers N., Goossens D., Engelborghs S., Pals P., Pickut B., Van den Broeck M., Corsmit E., Cras P., De Deyn P.P., Del-Favero J., Van Broeckhoven C., Theuns J. Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population. Hum. Mutat. 2009, 30:1054-1061.
152. Oaks A.W., Frankfurt M., Finkelstein D.I., Sidhu A. Age-dependent effects of A53T alpha-synuclein on behavior and dopaminergic function. PLoS One 2013, 8:e60378.
153. Olanow C.W., Brundin P. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?. Mov. Disord. 2013, 28:31-40.
154. Oueslati A., Paleologou K.E., Schneider B.L., Aebischer P., Lashuel H.A. Mimicking phosphorylation at serine 87 inhibits the aggregation of human alpha-synuclein and protects against its toxicity in a rat model of Parkinson's disease. J. Neurosci. 2012, 32:1536-1544.
155. Ozansoy M., Basak A.N. The central theme of Parkinson's disease: alpha-synuclein. Mol. Neurobiol. 2013, 47:460-465.
156. Pals P., Lincoln S., Manning J., Heckman M., Skipper L., Hulihan M., Van den Broeck M., De Pooter T., Cras P., Crook J., Van Broeckhoven C., Farrer M.J. alpha-Synuclein promoter confers susceptibility to Parkinson's disease. Ann. Neurol. 2004, 56:591-595.
157. Pankratz N., Nichols W.C., Elsaesser V.E., Pauciulo M.W., Marek D.K., Halter C.A., Wojcieszek J., Rudolph A., Pfeiffer R.F., Foroud T. Alpha-synuclein and familial Parkinson's disease. Mov. Disord. 2009, 24:1125-1131.
158. Papadimitriou A., Veletza V., Hadjigeorgiou G.M., Patrikiou A., Hirano M., Anastasopoulos I. Mutated alpha-synuclein gene in two Greek kindreds with familial PD: incomplete penetrance?. Neurology 1999, 52:651-654.
159. Parsian A.J., Racette B.A., Zhao J.H., Sinha R., Patra B., Perlmutter J.S., Parsian A. Association of alpha-synuclein gene haplotypes with Parkinson's disease. Parkinsonism Relat. Disord. 2007, 13:343-347.
160. Parsian A., Racette B., Zhang Z.H., Chakraverty S., Rundle M., Goate A., Perlmutter J.S. Mutation, sequence analysis, and association studies of alpha-synuclein in Parkinson's disease. Neurology 1998, 51:1757-1759.
161. Pastor P., Muñoz E., Ezquerra M., Obach V., Martí M.J., Valldeoriola F., Tolosa E., Oliva R. Analysis of the coding and the 5' flanking regions of the alpha-synuclein gene in patients with Parkinson's disease. Mov. Disord. 2001, 16:1115-1119.
162. Paumier K.L., Sukoff Rizzo S., Berger Z., Chen Y., Gonzales C., Kaftan E., Li L., Lotarski S., Monaghan M., Shen W., Stolyar P., Vasilyev D., Zaleska M., D Hirst W., Dunlop J. Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's disease. PLoS One 2013, 8:e70274.
163. Peng J., Andersen J.K. Mutant alpha-synuclein and aging reduce neurogenesis in the acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Aging Cell 2011, 10:255-262.
164. Pihlstrom L., Toft M. Genetic variability in SNCA and Parkinson's disease. Neurogenetics 2011, 12:283-293.
165. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
166. Proukakis C., Dudzik C.G., Brier T., Mackay D.S., Cooper J.M., Millhauser G.L., Houlden H., Schapira A.H. A novel alpha-synuclein missense mutation in Parkinson disease. Neurology 2013, 80:1062-1064.
167. Proukakis C., Houlden H., Schapira A.H. Somatic alpha-synuclein mutations in Parkinson's disease: hypothesis and preliminary data. Mov. Disord. 2013, 28:705-712.
168. Puschmann A. Monogenic Parkinson's disease and parkinsonism: clinical phenotypes and frequencies of known mutations. Parkinsonism Relat. Disord. 2013, 19:407-415.
169. Puschmann A., Bhidayasiri R., Weiner W.J. Synucleinopathies from bench to bedside. Parkinsonism Relat. Disord. 2012, 18S1:S24-S27.
170. Puschmann A., Wszolek Z.K., Farrer M., Gustafson L., Widner H., Nilsson C. Alpha-synuclein multiplications with parkinsonism, dementia or progressive myoclonus?. Parkinsonism Relat. Disord. 2009, 15:390-392.
171. Puschmann A., Ross O.A., Vilariño-Güell C., Lincoln S.J., Kachergus J.M., Cobb S.A., Lindquist S.G., Nielsen J.E., Wszolek Z.K., Farrer M., Widner H., van Westen D., Hägerström D., Markopoulou K., Chase B.A., Nilsson K., Reimer J., Nilsson C. A Swedish family with de novo alpha-synuclein A53T mutation: evidence for early cortical dysfunction. Parkinsonism Relat. Disord. 2009, 15:627-632.
172. Quadri, M., Fang, M., Picillo, M., Olgiati, S., Breedveld, G.J., Graafland, J., Wu, B., Xu, F., Erro, R., Amboni, M., Pappatà, S., Quarantelli, M., Annesi, G., Quattrone, A., Chien, H.F., Barbosa, E.R., International Parkinsonism Genetics Network, Oostra, B.A., Barone, P., Wang, J., Bonifati, V., 2013. Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset Parkinsonism. Hum. Mutat. 34, 1208-1215.
173. Rajput A., Vilariño-Güell C., Rajput M.L., Ross O.A., Soto-Ortolaza A.I., Lincoln S.J., Cobb S.A., Heckman M.G., Farrer M.J., Rajput A. Alpha-synuclein polymorphisms are associated with Parkinson's disease in a Saskatchewan population. Mov. Disord. 2009, 24:2411-2414.
174. Recchia A., Rota D., Debetto P., Peroni D., Guidolin D., Negro A., Skaper S.D., Giusti P. Generation of a alpha-synuclein-based rat model of Parkinson's disease. Neurobiol. Dis. 2008, 30:8-18.
175. Richfield E.K., Thiruchelvam M.J., Cory-Slechta D.A., Wuertzer C., Gainetdinov R.R., Caron M.G., Di Monte D.A., Federoff H.J. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp. Neurol. 2002, 175:35-48.
176. Ritz B., Rhodes S.L., Bordelon Y., Bronstein J. alpha-Synuclein genetic variants predict faster motor symptom progression in idiopathic Parkinson disease. PLoS One 2012, 7:e36199.
177. Ross O.A., Gosal D., Stone J.T., Lincoln S.J., Heckman M.G., Irvine G.B., Johnston J.A., Gibson J.M., Farrer M.J., Lynch T. Familial genes in sporadic disease: common variants of alpha-synuclein gene associate with Parkinson's disease. Mech. Ageing Dev. 2007, 128:378-382.
178. Rothman S.M., Griffioen K.J., Vranis N., Ladenheim B., Cong W.N., Cadet J.L., Haran J., Martin B., Mattson M.P. Neuronal expression of familial Parkinson's disease A53T alpha-synuclein causes early motor impairment, reduced anxiety and potential sleep disturbances in mice. J. Parkinsons Dis. 2013, 3:215-229.
179. Saiki S., Sato S., Hattori N. Molecular pathogenesis of Parkinson's disease: update. J. Neurol. Neurosurg. Psychiatry 2012, 83:430-436.
180. Sato H., Arawaka S., Hara S., Fukushima S., Koga K., Koyama S., Kato T. Authentically phosphorylated alpha-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease. J. Neurosci. 2011, 31:16884-16894.
181. Schlüter O.M., Fornai F., Alessandrí M.G., Takamori S., Geppert M., Jahn R., Südhof T.C. Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Neuroscience 2003, 118:985-1002.
182. Schmidt S., Linnartz B., Mendritzki S., Sczepan T., Lübbert M., Stichel C.C., Lübbert H. Genetic mouse models for Parkinson's disease display severe pathology in glial cell mitochondria. Hum. Mol. Genet. 2011, 20:1197-1211.
183. Scott W.K., Yamaoka L.H., Stajich J.M., Scott B.L., Vance J.M., Roses A.D., Pericak-Vance M.A., Watts R.L., Nance M., Hubble J., Koller W., Stern M.B., Colcher A., Allen F.J., Hiner B.C., Jankovic J., Ondo W., Laing N.G., Mastaglia F., Goetz C., Pappert E., Small G.W., Masterman D., Haines J.L., Davies T.L. The alpha-synuclein gene is not a major risk factor in familial Parkinson disease. Neurogenetics 1999, 2:191-192.
184. Sekine T., Kagaya H., Funayama M., Li Y., Yoshino H., Tomiyama H., Hattori N. Clinical course of the first Asian family with Parkinsonism related to SNCA triplication. Mov. Disord. 2010, 25:2871-2875.
185. Shin C.W., Kim H.J., Park S.S., Kim S.Y., Kim J.Y., Jeon B.S. Two Parkinson's disease patients with alpha-synuclein gene duplication and rapid cognitive decline. Mov. Disord. 2010, 25:957-959.
186. Singleton A.B., Farrer M.J., Bonifati V. The genetics of Parkinson's disease: progress and therapeutic implications. Mov. Disord. 2013, 28:14-23.
187. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., Gwinn-Hardy K. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
188. Sironi F., Trotta L., Antonini A., Zini M., Ciccone R., Della Mina E., Meucci N., Sacilotto G., Primignani P., Brambilla T., Coviello D.A., Pezzoli G., Goldwurm S. alpha-Synuclein multiplication analysis in Italian familial Parkinson disease. Parkinsonism Relat. Disord. 2010, 16:228-231.
189. Smith W.W., Liu Z., Liang Y., Masuda N., Swing D.A., Jenkins N.A., Copeland N.G., Troncoso J.C., Pletnikov M., Dawson T.M., Martin L.J., Moran T.H., Lee M.K., Borchelt D.R., Ross C.A. Synphilin-1 attenuates neuronal degeneration in the A53T alpha-synuclein transgenic mouse model. Hum. Mol. Genet. 2010, 19:2087-2098.
190. Sotiriou E., Vassilatis D.K., Vila M., Stefanis L. Selective noradrenergic vulnerability in alpha-synuclein transgenic mice. Neurobiol. Aging 2010, 31:2103-2114.
191. Spadafora P., Annesi G., Pasqua A.A., Serra P., Cirò Candiano I.C., Carrideo S., Tarantino P., Civitelli D., De Marco E.V., Nicoletti G., Annesi F., Quattrone A. NACP-REP1 polymorphism is not involved in Parkinson's disease: a case-control study in a population sample from southern Italy. Neurosci. Lett. 2003, 351:75-78.
192. Spira P.J., Sharpe D.M., Halliday G., Cavanagh J., Nicholson G.A. Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann. Neurol. 2001, 49:313-319.
193. Sundal C., Fujioka S., Uitti R.J., Wszolek Z.K. Autosomal dominant Parkinson's disease. Parkinsonism Relat. Disord. 2012, 18S1:S7-S10.
194. Tan E.K., Chai A., Teo Y.Y., Zhao Y., Tan C., Shen H., Chandran V.R., Teoh M.L., Yih Y., Pavanni R., Wong M.C., Puvan K., Lo Y.L., Yap E. Alpha-synuclein haplotypes implicated in risk of Parkinson's disease. Neurology 2004, 62:128-131.
195. Tan E.K., Tan C., Shen H., Chai A., Lum S.Y., Teoh M.L., Yih Y., Wong M.C., Zhao Y. Alpha synuclein promoter and risk of Parkinson's disease: microsatellite and allelic size variability. Neurosci. Lett. 2003, 336:70-72.
196. Tan E.K., Matsuura T., Nagamitsu S., Khajavi M., Jankovic J., Ashizawa T. Polymorphism of NACP-Rep1 in Parkinson's disease: an etiologic link with essential tremor?. Neurology 2000, 54:1195-1198.
197. Taschenberger G., Garrido M., Tereshchenko Y., Bähr M., Zweckstetter M., Kügler S. Aggregation of alphaSynuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons. Acta Neuropathol. 2012, 123:671-683.
198. Teive H.A., Raskin S., Iwamoto F.M., Germiniani F.M., Baran M.H., Werneck L.C., Allan N., Quagliato E., Leroy E., Ide S.E., Polymeropoulos M.H. The G209A mutation in the alpha-synuclein gene in Brazilian families with Parkinson's disease. Arq. Neuropsiquiatr. 2001, 59:722-724.
199. Theodore S., Cao S., Mclean P.J., Standaert D.G. Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J. Neuropathol. Exp. Neurol. 2008, 67:1149-1158.
200. Theuns J., Van Broeckhoven C. alpha-Synuclein gene duplications in sporadic Parkinson disease. Neurology 2008, 70:7-9.
201. Tofaris G.K., Garcia Reitböck P., Humby T., Lambourne S.L., O'connell M., Ghetti B., Gossage H., Emson P.C., Wilkinson L.S., Goedert M., Spillantini M.G. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. J. Neurosci. 2006, 26:3942-3950.
202. Tokuda T., Salem S.A., Allsop D., Mizuno T., Nakagawa M., Qureshi M.M., Locascio J.J., Schlossmacher M.G., El-Agnaf O.M. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 2006, 349:162-166.
203. Troiano A.R., Cazeneuve C., Le Ber I., Bonnet A.M., Lesage S., Brice A. Re: Alpha-synuclein gene duplication is present in sporadic Parkinson disease. Neurology 2008, 71:1295.
204. Tsika E., Moysidou M., Guo J., Cushman M., Gannon P., Sandaltzopoulos R., Giasson B.I., Krainc D., Ischiropoulos H., Mazzulli J.R. Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration. J. Neurosci. 2010, 30:3409-3418.
205. Ubeda-Bañon I., Saiz-Sanchez D., de la Rosa-Prieto C., Martinez-Marcos A. alpha-Synuclein in the olfactory system of a mouse model of Parkinson's disease: correlation with olfactory projections. Brain Struct. Funct. 2012, 217:447-458.
206. Uchiyama T., Ikeuchi T., Ouchi Y., Sakamoto M., Kasuga K., Shiga A., Suzuki M., Ito M., Atsumi T., Shimizu T., Ohashi T. Prominent psychiatric symptoms and glucose hypometabolism in a family with a SNCA duplication. Neurology 2008, 71:1289-1291.
207. Unger E.L., Eve D.J., Perez X.A., Reichenbach D.K., Xu Y., Lee M.K., Andrews A.M. Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human alpha-synuclein in mice. Neurobiol. Dis. 2006, 21:431-443.
208. van der Putten H., Wiederhold K.H., Probst A., Barbieri S., Mistl C., Danner S., Kauffmann S., Hofele K., Spooren W.P., Ruegg M.A., Lin S., Caroni P., Sommer B., Tolnay M., Bilbe G. Neuropathology in mice expressing human alpha-synuclein. J. Neurosci. 2000, 20:6021-6029.
209. Vaughan J.R., Farrer M.J., Wszolek Z.K., Gasser T., Durr A., Agid Y., Bonifati V., Demichele G., Volpe G., Lincoln S., Breteler M., Meco G., Brice A., Marsden C.D., Hardy J., Wood N.W. Sequencing of the alpha-synuclein gene in a large series of cases of familial Parkinson's disease fails to reveal any further mutations. The European Consortium on Genetic Susceptibility in Parkinson's Disease (GSPD). Hum. Mol. Genet. 1998, 7:751-753.
210. Vaughan J., Durr A., Tassin J., Bereznai B., Gasser T., Bonifati V., De Michele G., Fabrizio E., Volpe G., Bandmann O., Johnson W.G., Golbe L.I., Breteler M., Meco G., Agid Y., Brice A., Marsden C.D., Wood N.W. The alpha-synuclein Ala53Thr mutation is not a common cause of familial Parkinson's disease: a study of 230 European cases. European Consortium on Genetic Susceptibility in Parkinson's Disease. Ann. Neurol. 1998, 44:270-273.
211. Veletza S., Bostatzopoulou S., Hantzigeorgiou G., Kazis A., Papadimitriou A. α-Synuclein mutation associated with familial Parkinson's disease in two new Greek kindred. J. Neurol. 1999, 246:I/43.
212. Vishwanathan Padmaja M., Jayaraman M., Srinivasan A.V., Srikumari Srisailapathy C.R., Ramesh A. The SNCA (A53T, A30P, E46K) and LRRK2 (G2019S) mutations are rare cause of Parkinson's disease in South Indian patients. Parkinsonism Relat. Disord. 2012, 18:801-802.
213. Volles M.J., Lansbury P.T. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 2003, 42:7871-7878.
214. Voutsinas G.E., Stavrou E.F., Karousos G., Dasoula A., Papachatzopoulou A., Syrrou M., Verkerk A.J., van der Spek P., Patrinos G.P., Stöger R., Athanassiadou A. Allelic imbalance of expression and epigenetic regulation within the alpha-synuclein wild-type and p.Ala53Thr alleles in Parkinson disease. Hum. Mutat. 2010, 31:685-691.
215. Wakamatsu M., Ishii A., Iwata S., Sakagami J., Ukai Y., Ono M., Kanbe D., Muramatsu S., Kobayashi K., Iwatsubo T., Yoshimoto M. Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice. Neurobiol. Aging 2008, 29:574-585.
216. Wakamatsu M., Iwata S., Funakoshi T., Yoshimoto M. Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease. J. Neurosci. Res. 2008, 86:640-646.
217. Wakamatsu M., Ishii A., Ukai Y., Sakagami J., Iwata S., Ono M., Matsumoto K., Nakamura A., Tada N., Kobayashi K., Iwatsubo T., Yoshimoto M. Accumulation of phosphorylated alpha-synuclein in dopaminergic neurons of transgenic mice that express human alpha-synuclein. J. Neurosci. Res. 2007, 85:1819-1825.
218. Wan O.W., Chung K.K. The role of alpha-synuclein oligomerization and aggregation in cellular and animal models of Parkinson's disease. PLoS One 2012, 7:e38545.
219. Wang C.K., Chen C.M., Chang C.Y., Chang K.H., Chen I.C., Li M.L., Lee-Chen G.J., Wu Y.R. alpha-Synuclein promoter RsaI T-to-C polymorphism and the risk of Parkinson's disease. J. Neural Transm. 2006, 113:1425-1433.
220. Wang L., Fleming S.M., Chesselet M.F., Taché Y. Abnormal colonic motility in mice overexpressing human wild-type alpha-synuclein. Neuroreport 2008, 19:873-876.
221. Wang W.W., Khajavi M., Patel B.J., Beach J., Jankovic J., Ashizawa T. The G209A mutation in the alpha-synuclein gene is not detected in familial cases of Parkinson disease in non-Greek and/or Italian populations. Arch. Neurol. 1998, 55:1521-1523.
222. Warner T.T., Schapira A.H. The role of the alpha-synuclein gene mutation in patients with sporadic Parkinson's disease in the United Kingdom. J. Neurol. Neurosurg. Psychiatry 1998, 65:378-379.
223. Wider C., Skipper L., Solida A., Brown L., Farrer M., Dickson D., Wszolek Z.K., Vingerhoets F.J. Autosomal dominant dopa-responsive parkinsonism in a multigenerational Swiss family. Parkinsonism Relat. Disord. 2008, 14:465-470.
224. Williams-Gray C.H., Goris A., Foltynie T., Brown J., Maranian M., Walton A., Compston D.A., Sawcer S.J., Barker R.A. No alterations in alpha-synuclein gene dosage observed in sporadic Parkinson's disease. Mov. Disord. 2006, 21:731-732.
225. Winkler S., Hagenah J., Lincoln S., Heckman M., Haugarvoll K., Lohmann-Hedrich K., Kostic V., Farrer M., Klein C. alpha-Synuclein and Parkinson disease susceptibility. Neurology 2007, 69:1745-1750.
226. Winner B., Jappelli R., Maji S.K., Desplats P.A., Boyer L., Aigner S., Hetzer C., Loher T., Vilar M., Campioni S., Tzitzilonis C., Soragni A., Jessberger S., Mira H., Consiglio A., Pham E., Masliah E., Gage F.H., Riek R. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:4194-4199.
227. Wu-Chou Y.H., Chen Y.T., Yeh T.H., Chang H.C., Weng Y.H., Lai S.C., Huang C.L., Chen R.S., Huang Y.Z., Chen C.C., Hung J., Chuang W.L., Lin W.Y., Chen C.H., Lu C.S. Genetic variants of SNCA and LRRK2 genes are associated with sporadic PD susceptibility: a replication study in a Taiwanese cohort. Parkinsonism Relat. Disord. 2013, 19:251-255.
228. Xiromerisiou G., Hadjigeorgiou G.M., Gourbali V., Johnson J., Papakonstantinou I., Papadimitriou A., Singleton A.B. Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variants. Eur. J. Neurol. 2007, 14:7-11.
229. Yamada M., Iwatsubo T., Mizuno Y., Mochizuki H. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. J. Neurochem. 2004, 91:451-461.
230. Yamakado H., Moriwaki Y., Yamasaki N., Miyakawa T., Kurisu J., Uemura K., Inoue H., Takahashi M., Takahashi R. alpha-Synuclein BAC transgenic mice as a model for Parkinson's disease manifested decreased anxiety-like behavior and hyperlocomotion. Neurosci. Res. 2012, 73:173-177.
231. Yang Y.X., Wood N.W., Latchman D.S. Molecular basis of Parkinson's disease. Neuroreport 2009, 20:150-156.
232. Yavich L., Oksman M., Tanila H., Kerokoski P., Hiltunen M., van Groen T., Puolivali J., Männistö P.T., García-Horsman A., Macdonald E., Beyreuther K., Hartmann T., Jäkälä P. Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein. Neurobiol. Dis. 2005, 20:303-313.
233. Yavich L., Tanila H., Vepsäläinen S., Jäkälä P. Role of alpha-synuclein in presynaptic dopamine recruitment. J. Neurosci. 2004, 24:11165-11170.
234. Yonova-Doing E., Atadzhanov M., Quadri M., Kelly P., Shawa N., Musonda S.T., Simons E.J., Breedveld G.J., Oostra B.A., Bonifati V. Analysis of LRRK2, SNCA, Parkin, PINK1, and DJ-1 in Zambian patients with Parkinson's disease. Parkinsonism Relat. Disord. 2012, 18:567-571.
235. Yu L., Xu P., He X., Hu F., Lin Z., Zhu M., Liu Z., He L., Xu Y. SNP rs7684318 of the alpha-synuclein gene is associated with Parkinson's disease in the Han Chinese population. Brain Res. 2010, 1346:262-265.
236. Yuan L., Song Z., Xu H., Gu S., Zhu A., Gong L., Zhao Y., Deng H. EIF4G1 Ala502Val and Arg1205His variants in Chinese patients with Parkinson disease. Neurosci. Lett. 2013, 543:69-71.
237. Zareparsi S., Kaye J., Camicioli R., Kramer P., Nutt J., Bird T., Litt M., Payami H. Analysis of the alpha-synuclein G209A mutation in familial Parkinson's disease. Lancet 1998, 351:37-38.
238. Zarranz J.J., Alegre J., Gómez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atarés B., Llorens V., Gomez Tortosa E., del Ser T., Muñoz D.G., de Yebenes J.G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55:164-173.